Innovodigm

Innovodigm is a life sciences company developing a microneedle-based platform for transdermal delivery of vaccines and biologics. The firm's primary product, Theroptach, is a thermostable vaccine patch designed to address significant logistical challenges in global immunization programs. By enabling painless vaccine administration without the need for cold chain infrastructure or trained medical personnel, Theroptach targets the issue of vaccine inaccessibility in remote regions. The World Health Organization estimates that up to 50% of vaccines are wasted annually due to temperature control failures, a problem this technology aims to solve. The product also seeks to eliminate wastage associated with multidose vials.

Beyond its initial vaccine delivery system, Innovodigm's product pipeline includes a nanoporous gel for wound healing. This patented formulation, derived from natural ingredients like curcumin, is designed for sustained drug release to accelerate recovery and reduce scar formation. The company is also developing a drug testing platform for phase 0 clinical trials. This platform intends to mimic human organ interfaces, offering a more predictive alternative to rodent-based testing models for studying the effects of new drugs.

Keywords: microneedle patch, transdermal delivery, vaccine logistics, thermostable vaccines, biologics delivery, cold chain, drug testing platform, wound healing, nanoporous gel, Theroptach